NEW HAVEN, Conn., March 7, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2013.
For the three months ended December 31, 2013, the Company reported a net loss of $13.4 million, compared to a net loss of $11.2 million in the three months ended December 31, 2012. For the full year ended December 31, 2013, the Company’s net loss was $59.0 million, or $0.63 per share, compared to a net loss of $47.1 million for the year ended December 31, 2012, or $0.64 per share. Cash, cash equivalents, marketable securities and interest receivable at December 31, 2013 were $159.1 million.
Help employers find you! Check out all the jobs and post your resume.
